Bergenbio First Quarter Results 2024: Advancing To The Next Stage Of Development

BERGEN, Norway, May 29, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL

Related Keywords

Texas ,United States ,Oslo ,Norway ,Lilleby ,Øtfold ,United Kingdom ,Norwegian ,Prnewswire Bergenbio ,Martin Olin ,Mays Cancer Center ,Oslo Stock Exchange ,National Cancer Institute ,Safety Monitoring Board ,Texas Health Science Center ,San Antonio ,Chief Executive Officer ,Financial Report ,Financial Reports ,Abuse Regulation ,Norwegian Securities Trading ,